We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC
SGMO

Delisted

SGMO was delisted on the 4th of May, 2026.

Back to rankings

188 hedge funds and large institutions have $370M invested in SANGAMO THERAPEUTICS INC in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 74 increasing their positions, 46 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more call options, than puts

Call options by funds: $2.56M | Put options by funds: $1.54M

61% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 46

6.98% more ownership

Funds ownership: 54.16% → 61.14% (+7%)

4% less funds holding

Funds holding: 195 → 188 (-7)

14% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 21

19% less capital invested

Capital invested by funds: $458M → $370M (-$87.4M)

Holders
188
Holders Change
-7
Holders Change %
-3.59%
% of All Funds
3.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
74
Reduced
46
Closed
21
Calls
$2.56M
Puts
$1.54M
Net Calls
+$1.02M
Net Calls Change
-$672K

Top Buyers

Rank Fund Capital Flow
1
RCMU
Rokos Capital Management (UK)
United Kingdom
+$8.86M
2
WA
Wasatch Advisors
Utah
+$7.85M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$6.01M
4
CC
Casdin Capital
New York
+$4.32M
5
BlackRock
BlackRock
New York
+$3.25M

Top Sellers

Rank Fund Capital Flow
1
GLA
Great Lakes Advisors
Illinois
-$3.04M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$1.53M
3
PAM
Panagora Asset Management
Massachusetts
-$1.16M
4
UBS Group
UBS Group
Switzerland
-$1.14M
5
CI Investments Inc
CI Investments Inc
Ontario, Canada
-$875K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
151
Bourgeon Capital Management
Connecticut
$11K – – –
TWC
152
TD Waterhouse Canada
Ontario, Canada
$10.8K – – –
SPIA
153
Steward Partners Investment Advisory
New York
$10K -$3.12K -722 -22%
BWP
154
Baldwin Wealth Partners
Massachusetts
$10K – – –
BFEC
155
Benjamin F. Edwards & Company
Missouri
$10K – – –
EDRH
156
Edmond de Rothschild Holding
Switzerland
$10K +$10.8K +2,500 New
Baillie Gifford & Co
157
Baillie Gifford & Co
United Kingdom
$10K +$10.9K +2,510 New
AF
158
Advisornet Financial
Minnesota
$9K – – –
AP
159
Arlington Partners
Alabama
$8K – – –
IAMOG
160
Investors Asset Management of Georgia
Georgia
$7K +$7.78K +1,800 New
CAPTRUST Financial Advisors
161
CAPTRUST Financial Advisors
North Carolina
$5K -$3K -693 -36%
TWA
162
TCI Wealth Advisors
Arizona
$5K +$3.58K +828 +166%
AF
163
Allworth Financial
California
$4K – – –
FCMT
164
Founders Capital Management (Texas)
Texas
$4K – – –
HWM
165
HighMark Wealth Management
Minnesota
$4K – – –
WT
166
Whittier Trust
California
$4K – – –
RIM
167
Rockbridge Investment Management
New York
$3.75K – – –
Rockefeller Capital Management
168
Rockefeller Capital Management
New York
$3K -$4.81K -1,112 -55%
BC
169
Burleson & Co
California
$3K – – –
Daiwa Securities Group
170
Daiwa Securities Group
Japan
$2K – – –
GRP
171
Global Retirement Partners
California
$2K – – –
S
172
SignatureFD
Georgia
$2K +$817 +189 +104%
CWM
173
Castle Wealth Management
Florida
$2K +$1.73K +400 New
APA
174
American Portfolios Advisors
New York
$1.86K – – –
AFG
175
Albion Financial Group
Utah
$1K – – –
5 6
7
8 9

SGMO Hedge Fund Activity: Q2 2022 in Review

188 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q2 2022, worth a combined $370M — down 19% from $458M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of SGMO and 18 opened new positions — a net loss of 3 holders — while 46 trimmed existing stakes and 74 added.

The largest buyer was Rokos Capital Management (UK), adding an estimated $8.86M. The largest seller was Great Lakes Advisors, exiting entirely with an estimated $3.04M sold.

  • 188 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q2 2022, down from 195 in Q1 2022.
  • Funds reported $370M of SANGAMO THERAPEUTICS INC stock for Q2 2022, down 19% quarter-over-quarter.
  • 18 funds opened new SANGAMO THERAPEUTICS INC positions in Q2 2022 and 21 closed out, a net change of -3 holders.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q2 2022 was Rokos Capital Management (UK), an estimated $8.86M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q2 2022 was Great Lakes Advisors, an estimated $3.04M sold.

Based on aggregated 13F filings for Q2 2022.